ABSTRACT
Vulvovaginal candidiasis (VVC) is an opportunistic infection caused by a fungus of the Candida genus, affecting approximately 75 % of women during their lifetime. Fungal resistance cases and adverse effects have been the main challenges of oral therapies. In this study, the topical application of thin films containing fluconazole (FLU) and thymol (THY) was proposed to overcome these problems. Vaginal films based only on chitosan (CH) or combining this biopolymer with pectin (PEC) or hydroxypropylmethylcellulose acetate succinate (HPMCAS) were developed by the solvent casting method. In addition to a higher swelling index, CH/HPMCAS films showed to be more plastic and flexible than systems prepared with CH/PEC or only chitosan. Biopolymers and FLU were found in an amorphous state, contributing to explaining the rapid gel formation after contact with vaginal fluid. High permeability rates of FLU were also found after its immobilization into thin films. The presence of THY in polymer films increased the distribution of FLU in vaginal tissues and resulted in improved anti-Candida activity. A significant activity against the resistant C. glabrata was achieved, reducing the required FLU dose by 50 %. These results suggest that the developed polymer films represent a promising alternative for the treatment of resistant vulvovaginal candidiasis, encouraging further studies in this context.
Subject(s)
Antifungal Agents , Candidiasis, Vulvovaginal , Fluconazole , Thymol , Female , Candidiasis, Vulvovaginal/drug therapy , Candidiasis, Vulvovaginal/microbiology , Fluconazole/pharmacology , Fluconazole/chemistry , Fluconazole/administration & dosage , Antifungal Agents/pharmacology , Antifungal Agents/chemistry , Antifungal Agents/administration & dosage , Biopolymers/chemistry , Thymol/chemistry , Thymol/pharmacology , Drug Resistance, Fungal/drug effects , Humans , Chitosan/chemistry , Microbial Sensitivity Tests , Animals , Drug Carriers/chemistry , Permeability , Candida glabrata/drug effectsABSTRACT
Frequent and variant infections are caused by the virtue of opportunistic fungi pathogens. Candidiasis, aspergillosis, and mucormycosis are pathogenic microorganisms that give rise to vast fungal diseases that alternate between moderate to fatal in severity. The use of fluconazole as an antifungal drug was limited due to the acquired resistance in some types of Candida and other fungal species. This study aims to consolidate fluconazole's biological effectiveness against several pathogenic fungi. Six active monoterpenes (MTs) of carvacrol, linalool, geraniol, α-terpinene, citronellal, and nerolidol were selected and encapsulated in nanostructure lipid carrier (NLC) with (NLC-Flu-MTs) and/without (NLC-MTs) fluconazole in one nanoformulation to determine if they will act synergistically or not? The synthesized nanoformulation NLC-Flu-MTs and NLC-MTs exhibited very good particle size of 144.5 nm and 138.6 nm for size and zeta potential values of (- 23.5 mV) and (- 20.3 mV), respectively. Transmission electron microscope investigation confirmed that the synthesized NLCs have regular and spherical shape. The abundance and concentration of the six released monoterpenes were determined, as a novel approach, using GC-MS with very good results and validity. In-vitro antifungal screening was done before and after nano co-delivery against seven pathogenic, and aggressive fungi of Candida tropicalis, Candida krusei, Candida glabrata, Geotrichum Candidum, Candidaalbicans, Aspergillus Niger, and mucor circinelloides. Inhibition Zone diameter (IZD) and the minimum inhibitory concentration (MIC) were measured. Nanoformulations NLC-Flu-MTs and NLC-MTs manifested potential and unique biological susceptibility against all the tested microorganisms with reduced (MIC) values, especially against Candida Tropicalis (MIC = 0.97 µg/ml) which represents 16-fold of the value shown by NLC-MTs (MIC = 15.6 µg/ml) and 64-fold of fluconazole free before nanoformulation (MIC = 62.5 µg/ml). The efficiency of nanomaterials, particularly NLC-Flu-MTs, has become evident in the diminishing value of MIC which affirmed the synergism between fluconazole and the other six monoterpenes.
Subject(s)
Antifungal Agents , Fluconazole , Microbial Sensitivity Tests , Monoterpenes , Nanostructures , Antifungal Agents/pharmacology , Antifungal Agents/chemistry , Antifungal Agents/administration & dosage , Fluconazole/pharmacology , Fluconazole/chemistry , Monoterpenes/pharmacology , Monoterpenes/chemistry , Nanostructures/chemistry , Lipids/chemistry , Drug Synergism , Drug Carriers/chemistry , Particle Size , Candida/drug effectsABSTRACT
Fluconazole (FZ) is a potential antifungal compound for treating superficial and systemic candidiasis. However, the use of conventional oral drug products has some limitations. The development of buccal film may be a potential alternative to oral formulations for FZ delivery. The present study involved the development of novel FZ-loaded solid lipid nanoparticles (FZ-SLNs) in pectin solutions and the investigation of their particle characteristics. The particle sizes of the obtained FZ-SLNs were in the nanoscale range. To produce pectin films with FZ-SLNs, four formulations were selected based on the small particle size of FZ-SLNs and their suitable polydispersity index. The mean particle sizes of all chosen FZ-SLNs formulations did not exceed 131.7 nm, and the mean polydispersity index of each formulation was less than 0.5. The properties of films containing FZ-SLNs were then assessed. The preparation of all FZ-SLN-loaded pectin films provided the mucoadhesive matrices. The evaluation of mechanical properties unveiled the influence of particle size variation in FZ-SLNs on the integrity of the film. The Fourier-transform infrared spectra indicated that hydrogen bonds could potentially form between the pectin-based matrix and the constituents of FZ-SLNs. The differential scanning calorimetry thermogram of each pectin film with FZ-SLNs revealed that the formulation was thermally stable and behaved in a solid state at 37 °C. According to a drug release study, a sustained drug release pattern with a burst in the initial stage for all films may be advantageous for reducing the lag period of drug release. All prepared films with FZ-SLNs provided a sustained release of FZ over 6 h. The films containing FZ-SLNs with a small particle size provided good permeability across the porcine mucosa. All film samples demonstrated antifungal properties. These results suggest the potential utility of pectin films incorporating FZ-SLNs for buccal administration.
Subject(s)
Antifungal Agents , Fluconazole , Nanoparticles , Particle Size , Pectins , Pectins/chemistry , Nanoparticles/chemistry , Fluconazole/administration & dosage , Fluconazole/chemistry , Fluconazole/pharmacokinetics , Antifungal Agents/administration & dosage , Antifungal Agents/chemistry , Antifungal Agents/pharmacokinetics , Administration, Buccal , Lipids/chemistry , Drug Carriers/chemistry , Drug Liberation , Spectroscopy, Fourier Transform Infrared , Drug Delivery Systems/methods , Mouth Mucosa/metabolism , Mouth Mucosa/drug effects , Calorimetry, Differential Scanning , Animals , LiposomesABSTRACT
Fluconazole (FNL) is one of the first-line treatments for fungal keratitis as it is an effective broad-spectrum antimicrobial commonly administered orally or topically. However, FNL has a very low water solubility, limiting its drug formulation, therapeutic application, and bioavailability through tissues. To overcome these limitations, this study aimed to develop FNL inclusion complexes (FNL-IC) with cyclodextrin (α-cyclodextrin, sulfobutylether-ß-cyclodextrin, and hydroxypropyl-γ cyclodextrin) and incorporate it into a dissolvable microneedle (DMN) system to improve solubility and drug penetration. FNL-IC was evaluated for saturation solubility, Fourier transform infrared spectroscopy, differential scanning calorimetry, in vitro release, minimum inhibitory concentration, minimum fungicidal concentration, and time-killing assay. DMN-FNL-IC was evaluated for mechanical and insertion properties, surface pH, moisture absorption ability, water vapor transmission, and drug content recovery. Moreover, ocular kinetic, ex vivo antimicrobial, in vivo antifungal, and chorioallantoic membrane (HET-CAM) assays were conducted to assess the overall performance of the formulation. Mechanical strength and insertion properties revealed that DMN-FNL-IC has great mechanical and insertion properties. The in vitro release of FNL-IC was significantly improved, exhibiting a 9-fold increase compared to pure FNL. The ex vivo antifungal activity showed significant inhibition of Candida albicans from 6.54 to 0.73 log cfu/mL or 100-0.94%. In vivo numbers of colonies of 0.87 ± 0.13 log cfu/mL (F2), 4.76 ± 0.26 log cfu/mL (FNL eye drops), 3.89 ± 0.24 log cfu/mL (FNL ointments), and 8.04 ± 0.58 log cfu/mL (control) showed the effectiveness of DMN preparations against other standard commercial preparations. The HET-CAM assay showed that DMN-FNL-IC (F2) did not show any vascular damage. Finally, a combination of FNL-IC and DMN was developed appropriately for ocular delivery of FNL, which was safe and increased the effectiveness of treatments for fungal keratitis.
Subject(s)
Antifungal Agents , Candida albicans , Fluconazole , Keratitis , Fluconazole/pharmacology , Fluconazole/chemistry , Fluconazole/pharmacokinetics , Animals , Antifungal Agents/pharmacology , Antifungal Agents/chemistry , Antifungal Agents/pharmacokinetics , Keratitis/drug therapy , Keratitis/microbiology , Candida albicans/drug effects , Microbial Sensitivity Tests , Rabbits , Needles , Solubility , Eye Infections, Fungal/drug therapy , Eye Infections, Fungal/microbiologyABSTRACT
Candida species is one of the pathogenic fungi of the eye responsible for keratitis that frequently causes vision impairment and blindness. Effective treatment requires long-term use of antifungal drugs, which is opposed by the defensive mechanisms of the eye and inadequate corneal penetration. The objective of this study was to develop a carrier for prolonged ocular application of fluconazole (FLZ) to treat keratitis. FLZ was encapsulated into chitosan fibrous matrices (F1-F4) using different chitosan concentrations (0.02, 0.1, 0.5, and 1%w/v, respectively) by freeze-drying as a single-step technique. Studying the morphology and surface properties of the inserts revealed a porous matrix with fibrous features with a large surface area. Thermal stability and chemical compatibility were confirmed by DSC/TGA/DTA and FT-IR, respectively. Loading capacity (LC) and entrapment efficiency (EE) were determined. According to the in vitro release study, F4 (0.11 mg mg-1 LC and 87.53% EE) was selected as the optimum insert because it had the most sustained release, with 15.85% burst release followed by 75.62% release within 12 h. Ex vivo corneal permeation study revealed a 1.2-fold increase in FLZ permeation from F4 compared to FLZ aqueous solution. Also, in the in vivo pharmacokinetic study in rabbits, F4 increased the AUC0-8 of FLZ by 9.3-fold and its concentration in aqueous humor was maintained above the MIC through the experimentation time. Studies on cytotoxicity (MTT assay) provide evidence for the safety and biocompatibility of F4. Therefore, the freeze-dried FLZ-loaded chitosan fibrous insert could be a promising candidate for treating ocular keratitis.
Subject(s)
Antifungal Agents , Chitosan , Cornea , Fluconazole , Freeze Drying , Animals , Antifungal Agents/administration & dosage , Antifungal Agents/chemistry , Antifungal Agents/pharmacology , Antifungal Agents/pharmacokinetics , Rabbits , Fluconazole/administration & dosage , Fluconazole/chemistry , Fluconazole/pharmacokinetics , Fluconazole/pharmacology , Chitosan/chemistry , Chitosan/administration & dosage , Cornea/drug effects , Drug Liberation , Administration, Ophthalmic , Drug Carriers/chemistry , Drug Carriers/administration & dosage , Male , Keratitis/drug therapy , Keratitis/microbiology , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/pharmacokineticsABSTRACT
The root bark of Strychnos innocua has long been employed by traditional healers to treat a variety of ill health conditions including fungal infections. The objective of this study was to isolate, characterized and evaluate the antifungal potential (insilico approach) of some steroids from root bark of S. innocua. Conventional method of column chromatography was carried out on the ethyl acetate root bark extract of S. innocua, leading to the isolation of two steroids. On the basis of 1D NMR, 2D NMR, GC-ESI/MS analyses, and literature comparisons, the compounds were characterized as Stigmast-5-en-3ß-ol (1) and Campest-5-en-3ß-ol (2). This is the first time these compounds have been isolated from the plant. The results of the in silico modelling of the compounds 1, 2, and fluconazole (control drug) with the binding sites of SAP2 from Candida albicans (PDB: 1EAG) demonstrated that the binding energies were -8.3, -8.0, and -7.1 kcal/mol, respectively. However, the modelling with binding sites of a deglycating enzyme fructosamine oxidase from Aspergillus fumigatus (PDB: 3DJE) demonstrated that the binding energies were -5.9, -7.2, and -8.0 for Stigmast-5-en-3ß-ol (1) and Campest-5-en-3ß-ol (2), and fluconazole, respectively. In conclusion, the study found that Stigmast-5-en-3-ol and Campest-5-en-3-ol are both present in the root bark of S. innocua. The compounds exhibited promising interaction with the binding sites of the protein target (SAP2 from C. albicans) compare to fluconazole.
Subject(s)
Antifungal Agents , Steroids , Strychnos , Antifungal Agents/chemistry , Antifungal Agents/pharmacology , Computer Simulation , Fluconazole/chemistry , Fluconazole/pharmacology , Plant Bark/chemistry , Plant Roots/chemistry , Steroids/chemistry , Strychnos/chemistryABSTRACT
The occurrence of fungal infections has increased over the past two decades. It is observed that superficial fungal infections are treated by conventional dosage forms, which are incapable of treating deep infections due to the barrier activity possessed by the stratum corneum of the skin. This is why the need for a topical preparation with advanced penetration techniques has arisen. This research aimed to encapsulate fluconazole (FLZ) in a novasome in order to improve the topical delivery. The novasomes were prepared using the ethanol injection technique and characterized for percent entrapment efficiency (EE), particle size (PS), zeta potential (ZP), drug release, Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), scanning electron microscopy (SEM) and antifungal activity. The FN7 formulation with 94.45% EE, 110 nm PS and -24 ZP proved to be the best formulation. The FN7 formulation showed a 96% release of FLZ in 8 h. FTIR showed the compatibility of FLZ with excipients and DSC studies confirmed the thermal stability of FLZ in the developed formulation. The FN7 formulation showed superior inhibition of the growth of Candida albicans compared to the FLZ suspension using a resazurin reduction assay, suggesting high efficacy in inhibiting fungal growth.
Subject(s)
Fluconazole , Mycoses , Antifungal Agents/therapeutic use , Candida albicans , Drug Carriers/chemistry , Drug Delivery Systems/methods , Fluconazole/chemistry , Fluconazole/pharmacology , Mycoses/drug therapy , Particle SizeABSTRACT
With the widespread use of azole antifungals in the clinic, the drug resistance has been emerging continuously. In this work, we focus on boron trifluoride etherate catalyzed condensation of indole and salicylaldehydes to form bis(indolyl)methanes (BIMs) in high yields, and in vitro antifungal activity against Candida albicans were evaluated. The results showed that most phenol-derived BIMs combined with fluconazole (FLC) exhibited good antifungal activity against sensitive and drug-resistant C. albicans. Further mechanism study demonstrated that BI-10 combined with FLC could inhibit hyphal growth, result in ROS accumulation, and decrease mitochondrial membrane potential (MMP) as well as altering membrane permeability.
Subject(s)
Antifungal Agents/pharmacology , Candida albicans/drug effects , Fluconazole/pharmacology , Indoles/pharmacology , Methane/pharmacology , Phenols/pharmacology , Antifungal Agents/chemical synthesis , Antifungal Agents/chemistry , Dose-Response Relationship, Drug , Drug Resistance, Fungal/drug effects , Fluconazole/chemistry , Indoles/chemistry , Methane/chemistry , Microbial Sensitivity Tests , Molecular Structure , Phenols/chemistry , Structure-Activity RelationshipABSTRACT
Mefentrifluconazole, a new type of chiral triazole fungicide, is widely applied to control a variety of fungal diseases in crops. However, the toxicological effects of mefentrifluconazole on aquatic organisms are unknown, especially at the enantiomer level. In the present study, zebrafish were selected as a typical model for mefentrifluconazole enantiomer exposure. Metabolomic and transcription analyses were performed with 0.01 and 0.10 mg/L mefentrifluconazole and its enantiomers (i.e., rac-mfz/(-)-mfz/(+)-mfz) at 28 days. The 1H nuclear magnetic resonance (NMR)-based metabolomics analysis showed that 9, 10 and 4 metabolites were changed significantly in the rac-mfz, (+)-mfz and (-)-mfz treatment groups compared with the control group, respectively. The differential metabolites were related to energy metabolism, lipid metabolism and amino acid metabolism. The qRT-PCR analysis revealed that the expression of lipid metabolism-, apoptosis- and CYP-related genes in the livers of female zebrafish in rac-mfz and (+)-mfz was 1.61-108.92 times and 2.37-551.34 times higher than that in (-)-mfz, respectively. The results above indicate that exposure to mefentrifluconazole induced enantioselective liver toxicity in zebrafish. Our study underlined the importance of distinguishing different enantiomers, which will contribute to environmental protection.
Subject(s)
Energy Metabolism/drug effects , Fluconazole/analogs & derivatives , Fungicides, Industrial/toxicity , Liver/drug effects , Metabolome/drug effects , Transcriptome/drug effects , Zebrafish , Animals , Female , Fluconazole/chemistry , Fluconazole/toxicity , Fungicides, Industrial/chemistry , Gene Expression Profiling , Gene Expression Regulation , Lipid Metabolism/drug effects , Liver/metabolism , Liver/pathology , Male , Metabolomics , Molecular Structure , Proton Magnetic Resonance Spectroscopy , Sex Factors , Stereoisomerism , Structure-Activity Relationship , Zebrafish/genetics , Zebrafish/metabolismABSTRACT
The economic approaches for manufacturing the nanoparticles with physical and chemical effects and limited resistance to antibiotics have been progressed recently due to the rise of microbial resistance to antibiotics. This research aimed to study the antimicrobial efficacy of silver nanoparticles Ag, ZnO, and Tio2 nanoparticles against Salmonella typhimurium and Brucella abortus and Candida albicans. Two isolates of Salmonella and two isolates of Brucella abortus were isolated from food spastically meat and blood specimens, respectively. Candida albicans were isolated from the patient's mouth with oral candidiasis (oral thrush) and confirmed diagnosis by API 20C test. The antimicrobial susceptibility of Salmonella typhimurium and B. abortus isolates were performed against nine different antibiotics. Silver nanoparticles consisting of AgNPs size (90) nm, ZnO NPs size (20, 50) nm as well as TiO2 NPs size (10, 50) nm, were used. UV-Visible spectrophotometer was used to characterize silver nanoparticles. The highest resistance of Candida albicans was seen for fluconazole, Clotrimazole and Itraconazole. The results of the Minimum Inhibitory Concentration (MIC) of nanoparticles against Salmonella typhimurium showed the average MIC of Tio2-10nm and Tio2-50nm were 5000 and 2500 µg\ml for S1 and S2 isolates, respectively. The isolated Brucella abortus (B1 and B2) showed sensitivity to NPs with different MIC. The average MIC for Ag-90nm was 5000 and 2500 µg/ml for B1 and B2 isolates, respectively. The findings suggest NP solution has fungicidal and bactericidal impacts on the tested microorganisms so they can be suitable for multiple applications of the biomedical field such as developing new antimicrobial agents.
Subject(s)
Bacteria/drug effects , Candida albicans/drug effects , Metal Nanoparticles/administration & dosage , Silver/pharmacology , Titanium/pharmacology , Zinc Oxide/pharmacology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Antifungal Agents/administration & dosage , Antifungal Agents/chemistry , Antifungal Agents/pharmacology , Bacteria/classification , Bacteria/growth & development , Brucella abortus/drug effects , Brucella abortus/growth & development , Candida albicans/growth & development , Clotrimazole/administration & dosage , Clotrimazole/chemistry , Clotrimazole/pharmacology , Drug Resistance, Fungal , Fluconazole/administration & dosage , Fluconazole/chemistry , Fluconazole/pharmacology , Humans , Itraconazole/administration & dosage , Itraconazole/chemistry , Itraconazole/pharmacology , Metal Nanoparticles/chemistry , Microbial Sensitivity Tests/methods , Particle Size , Salmonella typhimurium/drug effects , Salmonella typhimurium/growth & development , Silver/administration & dosage , Silver/chemistry , Spectrophotometry/methods , Spectroscopy, Fourier Transform Infrared/methods , Titanium/administration & dosage , Titanium/chemistry , Zinc Oxide/administration & dosage , Zinc Oxide/chemistryABSTRACT
A simple, cost-effective and sensitive liquid chromatography-based bio-analytical method has been developed and validated for therapeutic drug monitoring of fluconazole (FLUC) in human serum. Integration of online mixed-mode solid-phase extraction (SPE) into the analytical system was the key for direct injection of untreated serum samples. A short protein-coated (PC) µBondapak CN silica column (PC-µB-CN-column) as a SPE tool and phosphate buffer saline (PBS) (pH 7.4) as an eluent were applied in the extraction step. PC-µB-CN-column operates in two different chromatographic modes. Using PBS, proteins were extracted from serum samples by size-exclusion liquid chromatography, while FLUC trapping was reversed-phase liquid chromatography dependent. FLUC was then eluted from the PC-µB-CN-column onto the quantification position using a mixture of acetonitrile-distilled deionized water (20:80, v/v) as an eluent and ODS analytical column. FLUC was separated at ambient temperature (22 ± 1 °C) and detected at 260 nm. The method was linear over the range of 200-10000 ng/mL. FLUC recovery in untreated serum samples ranged from 97.8 to 98.8% and showed good accuracy and precision. The reliability of the developed method was evaluated by studying the pharmacokinetic profile of FLUC in humans after an oral administration of a single 150 mg tablet.
Subject(s)
Chromatography, High Pressure Liquid/methods , Drug Monitoring/methods , Fluconazole/blood , Fluconazole/isolation & purification , Solid Phase Extraction/methods , Chromatography, Reverse-Phase/methods , Fluconazole/chemistry , Fluconazole/pharmacokinetics , Humans , Limit of Detection , Linear Models , Male , Reproducibility of ResultsABSTRACT
PURPOSE: The resistance of C. albicans to traditional antifungal drugs brings a great challenge to clinical treatment. To overcome the resistance, developing antifungal agent sensitizers has attracted considerable attention. This study aimed to determine the anti-Candida activity of BEH alone or BEH-FLC combination and to explore the underlying mechanisms. MATERIALS AND METHODS: In vitro antifungal effects were performed by broth microdilution assay and XTT reduction assay. Infected Galleria mellonella larvae model was used to determine the antifungal effects in vivo. Probes Fluo-3/AM, FITC-VAD-FMK and rhodamine 6G were used to study the influence of BEH and FLC on intracellular calcium concentration, metacaspase activity and drug efflux of C. albicans. RESULTS: BEH alone exhibited obvious antifungal activities against C. albicans. BEH plus FLC not only showed synergistic effects against planktonic cells and preformed biofilms within 8 h but also enhanced the antifungal activity in infected G. mellonella larvae. Mechanistic studies indicated that antifungal effects of drugs might be associated with the increasement of calcium concentration, activation of metacaspase activity to reduce virulence and anti-biofilms, but were not related to drug efflux. CONCLUSION: BEH alone or combined with FLC displayed potent antifungal activity both in vitro and in vivo, and the underlying mechanisms were related to reduced virulence factors.
Subject(s)
Antifungal Agents/pharmacology , Benserazide/pharmacology , Candida albicans/drug effects , Fluconazole/pharmacology , Animals , Antifungal Agents/chemistry , Benserazide/chemistry , Biofilms/drug effects , Dose-Response Relationship, Drug , Drug Resistance, Fungal/drug effects , Drug Therapy, Combination , Fluconazole/chemistry , Microbial Sensitivity Tests , MothsABSTRACT
Cytochrome P450 monooxygenase CYP51 (sterol 14α-demethylase) is a well-known target of the azole drug fluconazole for treating cryptococcosis, a life-threatening fungal infection in immune-compromised patients in poor countries. Studies indicate that mutations in CYP51 confer fluconazole resistance on cryptococcal species. Despite the importance of CYP51 in these species, few studies on the structural analysis of CYP51 and its interactions with different azole drugs have been reported. We therefore performed in silico structural analysis of 11 CYP51s from cryptococcal species and other Tremellomycetes. Interactions of 11 CYP51s with nine ligands (three substrates and six azoles) performed by Rosetta docking using 10,000 combinations for each of the CYP51-ligand complex (11 CYP51s × 9 ligands = 99 complexes) and hierarchical agglomerative clustering were used for selecting the complexes. A web application for visualization of CYP51s' interactions with ligands was developed (http://bioshell.pl/azoledocking/). The study results indicated that Tremellomycetes CYP51s have a high preference for itraconazole, corroborating the in vitro effectiveness of itraconazole compared to fluconazole. Amino acids interacting with different ligands were found to be conserved across CYP51s, indicating that the procedure employed in this study is accurate and can be automated for studying P450-ligand interactions to cater for the growing number of P450s.
Subject(s)
Amino Acids/metabolism , Azoles/metabolism , Basidiomycota/enzymology , Cytochrome P-450 Enzyme System/metabolism , Fluconazole/metabolism , Fungal Proteins/metabolism , Itraconazole/metabolism , Amino Acids/chemistry , Antifungal Agents/chemistry , Antifungal Agents/metabolism , Azoles/chemistry , Computer Simulation , Cytochrome P-450 Enzyme System/chemistry , Fluconazole/chemistry , Fungal Proteins/chemistry , Itraconazole/chemistry , Ligands , Models, Molecular , Phylogeny , Protein Binding , Protein Conformation , Substrate SpecificityABSTRACT
Inclusion complexes between cyclodextrins (CDs) and active pharmaceutical ingredients (APIs) have potential for pharmaceutical formulation. Since crystallization of a given complex may result in the isolation of multiple crystal forms, it is essential to characterize these forms with respect to their structures and physicochemical properties to optimize pharmaceutical candidate selection. Here, we report the preparation and characterization of two crystallographically distinct hydrated forms of an inclusion complex between ß-cyclodextrin (ß-CD) and the antifungal API fluconazole (FLU) as well as temperature-concentration conditions required for their individual isolation. Determination of crystal water contents was achieved using thermoanalytical methods. X-ray analyses revealed distinct structural differences between the triclinic (TBCDFLU, space group P1) and monoclinic (MBCDFLU, space group C2) crystal forms. Removal of the crystals from their mother liquors led to rapid dehydration of the MBCDFLU crystal, while the TBCDFLU crystal was stable, a result that could be reconciled with the distinct packing arrangements in the respective crystals. This study highlights (a) the importance of identifying possible multiple forms of a cyclodextrin API complex and controlling the crystallization conditions, and (b) the need to characterize such crystal forms to determine the extent to which their physicochemical properties may differ.
Subject(s)
Fluconazole/chemistry , Models, Molecular , beta-Cyclodextrins/chemistry , Crystallography, X-RayABSTRACT
There are many reports of falsified medicines that may cause harm to patients. A rapid and simple method of identifying falsified medicines that could be used in the field is required. Although Raman scattering spectroscopy has become popular as a non-destructive analysis, few validation experiments on falsified medicines that are actually distributed on the market have been conducted. In this study, we validated a discriminant analysis using an ultra-compact, portable, and low-cost Raman scattering spectrometer combined with multivariate analysis. The medicines were three types of erectile dysfunction therapeutic tablet and one type of antifungal tablet: tadalafil (Cialis), vardenafil hydrochloride (Levitra), sildenafil citrate (Viagra), and fluconazole (Diflucan), which is sometimes advertised as female Viagra. For each medicine, the authentic standard product and products obtained by personal import via the internet (genuine or falsified) were used. Discriminant analyses were performed on the Raman spectra combined with soft independent modeling of class analogy (SIMCA) and partial least squares discriminant analysis (PLS-DA). It was possible to identify all falsified samples by SIMCA using the standard product model for all four products. Using the PLS-DA using the PLS models of the four standard products, falsified Levitra and Diflucan samples were classified correctly, although some falsified Cialis and all Viagra samples also belonged to the standard class. In this study, SIMCA might be more suitable than PLS-DA for identifying falsified medicines. A spectroscopic module that combines the low-cost Raman scattering spectroscopy with SIMCA might contribute to the rapid identification of falsified medicines in the field.
Subject(s)
Counterfeit Drugs/analysis , Models, Chemical , Spectrum Analysis, Raman , Counterfeit Drugs/chemistry , Fluconazole/analysis , Fluconazole/chemistry , Least-Squares Analysis , Sildenafil Citrate/analysis , Sildenafil Citrate/chemistry , Tablets , Tadalafil , Vardenafil Dihydrochloride/analysis , Vardenafil Dihydrochloride/chemistryABSTRACT
A total of fourteen pyrazoline derivatives were synthesized through cyclo-condensation reactions by chalcone derivatives with different types of semicarbazide. These compounds were characterized by IR, 1D-NMR (1H, 13C and Distortionless Enhancement by Polarization Transfer - DEPT-135) and 2D-NMR (COSY, HSQC and HMBC) as well as mass spectroscopy analysis (HRMS). The synthesized compounds were tested for their antituberculosis activity against Mycobacterium tuberculosis H37Ra in vitro. Based on this activity, compound 4a showed the most potent inhibitory activity, with a minimum inhibitory concentration (MIC) value of 17 µM. In addition, six other synthesized compounds, 5a and 5c-5g, exhibited moderate activity, with MIC ranges between 60 µM to 140 µM. Compound 4a showed good bactericidal activity with a minimum bactericidal concentration (MBC) value of 34 µM against Mycobacterium tuberculosis H37Ra. Molecular docking studies for compound 4a on alpha-sterol demethylase was done to understand and explore ligand-receptor interactions, and to hypothesize potential refinements for the compound.
Subject(s)
14-alpha Demethylase Inhibitors/chemical synthesis , Antitubercular Agents/chemical synthesis , Bacterial Proteins/antagonists & inhibitors , Pyrazoles/chemical synthesis , Semicarbazides/chemical synthesis , Sterol 14-Demethylase/chemistry , 14-alpha Demethylase Inhibitors/pharmacology , Antitubercular Agents/pharmacology , Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , Catalytic Domain , Fluconazole/chemistry , Fluconazole/pharmacology , Isoniazid/chemistry , Isoniazid/pharmacology , Microbial Sensitivity Tests , Molecular Docking Simulation , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/enzymology , Mycobacterium tuberculosis/growth & development , Protein Binding , Protein Conformation , Protein Interaction Domains and Motifs , Pyrazoles/pharmacology , Semicarbazides/pharmacology , Sterol 14-Demethylase/metabolism , Structural Homology, Protein , ThermodynamicsABSTRACT
Cryptococcus is a globally distributed fungal pathogen that primarily afflicts immunocompromised individuals. The therapeutic options are limited and include mostly amphotericin B or fluconazole, alone or in combination. The extensive usage of antifungals allowed the selection of resistant pathogens posing threats to global public health. Histone deacetylase genes are involved in Cryptococcus virulence, and in pathogenicity and resistance to azoles in Candida albicans. Aiming to assess whether histone deacetylase genes are involved in antifungal response and in synergistic drug interactions, we evaluated the activity of amphotericin B, fluconazole, sulfamethoxazole, sodium butyrate or trichostatin A (histone deacetylase inhibitors), and hydralazine or 5- aza-2'-deoxycytidine (DNA methyl-transferase inhibitors) against different Cryptococcus neoformans strains, C. neoformans histone deacetylase null mutants and Cryptococcus gattii NIH198. The drugs were employed alone or in different combinations. Fungal growth after photodynamic therapy mediated by an aluminium phthalocyanine chloride nanoemulsion, alone or in combination with the aforementioned drugs, was assessed for the C. neoformans HDAC null mutant strains. Our results showed that fluconazole was synergistic with sodium butyrate or with trichostatin A for the hda1Δ/hos2Δ double mutant strain. Sulfamethoxazole was synergistic with sodium butyrate or with hydralazine also for hda1Δ/hos2Δ. These results clearly indicate a link between HDAC impairment and drug sensitivity. Photodynamic therapy efficacy on controlling the growth of the HDAC mutant strains was increased by amphotericin B, fluconazole, sodium butyrate or hydralazine. This is the first study in Cryptococcus highlighting the combined effects of antifungal drugs, histone deacetylase or DNA methyltransferase inhibitors and photodynamic therapy in vitro.
Subject(s)
Antifungal Agents/metabolism , Bacterial Proteins/genetics , Cryptococcosis/drug therapy , Cryptococcus neoformans/enzymology , Epigenesis, Genetic/drug effects , Histone Deacetylases/genetics , Indoles/metabolism , Organometallic Compounds/metabolism , Photochemotherapy/methods , Amphotericin B/chemistry , Butyric Acid/chemistry , Drug Synergism , Emulsions/chemistry , Fluconazole/chemistry , Gene Expression Regulation, Bacterial/drug effects , Humans , Hydroxamic Acids/chemistry , Indoles/pharmacology , Nanoparticles/chemistry , Organometallic Compounds/pharmacology , Sulfamethoxazole/chemistryABSTRACT
The aim of this work was to evaluate the influence of US on the properties of the fluconazole emulsions prepared using imidazolium-based ILs ([Cn C1im]Br). The effects of the preparation method (mechanical stirring or US), US amplitude, alkyl chain length (of [C12C1im]Br or [C16C1im]Br), and IL concentration on the physicochemical properties were evaluated. Properties such as droplet size, span index, morphology, viscosity encapsulation efficiency, and drug release profile were determined. The results showed that US-prepared emulsions had a smaller droplet size and smaller polydispersity (Span) than those prepared by mechanical stirring. Additionally, the results showed that emulsions prepared with [C16C1im]Br and US had spherical shapes and increased stability compared to emulsions prepared by MS, and also depended on the IL concentration. The emulsion prepared by US at 40% amplitude had increased encapsulation efficiency. US provided a decrease in the viscosity of emulsions containing [C12C1im]Br; however, in general, all emulsions had viscosity close to that of water. Emulsions containing [C16C1im]Br had the lowest viscosities of all the emulsions. The emulsions containing the IL [C16C1im]Br had more controlled release and a lower cumulative percentage of drug release. The IL concentration required to prepare these emulsions was lower than the amount of conventional surfactant required, which highlights the potential synergic effects of ILs and US in preparing emulsions of hydrophobic drugs.
Subject(s)
Fluconazole/chemistry , Ionic Liquids/chemistry , Ultrasonic Waves , Emulsions , Hydrophobic and Hydrophilic Interactions , Imidazoles/chemistry , Kinetics , Mechanical Phenomena , Particle Size , ViscosityABSTRACT
The aim of this work was to prepare and optimize mucoadhesive nanostructured lipid carrier (NLC) impregnated with fluconazole for better management of oral candidiasis. The NLCs were fabricated using an emulsification/sonication technique. The nanoparticles consisted of stearic acid, oleic acid, Pluronic F127, and lecithin. Box-Behnken design, artificial neural networking, and variable weight desirability were employed to optimize the joint effect of drug concentration in the drug/lipid mixture, solid lipid concentration in the solid/liquid lipid mixture, and surfactant concentration in the total mixture on size and entrapment. The optimized NLCs were coated with chitosan. The nanoparticles were characterized by surface charge, spectroscopic, thermal, morphological, mucoadhesion, release, histopathological, and antifungal properties. The nanoparticles are characterized by a particle size of 335 ± 13.5 nm, entrapment efficiency of 73.1 ± 4.9%, sustained release, minor histopathological effects on rabbit oral mucosa, and higher fungal inhibition efficiency for an extended period of time compared with fluconazole solution. Coating the nanoparticles with chitosan increased its adhesion to rabbit oral buccal mucosa and improved its anti-candidiasis activity. It is concluded that mucoadhesive lipid-based nanoparticles amplify the effect of fluconazole on Candida albicans in vitro. This finding warrants pre-clinical and clinical studies in oral candidiasis disease models to corroborate in vitro findings.
Subject(s)
Candidiasis, Oral , Fluconazole/pharmacology , Lipids/chemistry , Nanoparticles , Nanostructures , Animals , Candidiasis, Oral/drug therapy , Drug Carriers , Fluconazole/administration & dosage , Fluconazole/chemistry , Machine Learning , Particle Size , RabbitsABSTRACT
A drug-eluting coating applied onto biomedical devices and implants is an appropriate way to ensure that an inhibitory concentration of antimicrobial drugs is present at the device surface, thus preventing surface colonization and subsequent biofilm formation. In this study, a thin polymer coating was applied to materials, and it acted as a drug-delivery reservoir capable of surface delivery of the antifungal drug fluconazole to amounts up to 21 µg/cm2. The release kinetics into aqueous solution were quantified by UV spectroscopy and conformed to the Ritger-Peppas and Korsmeyer-Peppas model. Complementary microbiological assays were used to determine effectiveness against Candida albicans attachment and biofilm formation, and against the control heptylamine plasma polymer coating without drug loading, on which substantial fungal growth occurred. Fluconazole release led to marked antifungal activity in all assays, with log 1.6 reduction in CFUs/cm2. Cell viability assays and microscopy revealed that fungal cells attached to the fluconazole-loaded coating remained rounded and did not form hyphae and biofilm. Thus, in vitro screening results for fluconazole-releasing surface coatings showed efficacy in the prevention of the formation of Candida albicans biofilm.